Analyst Price Targets — CORT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 2, 2026 10:56 am | Swayampakula Ramakanth | H.C. Wainwright | $95.00 | $70.44 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Corcept Therapeutics (CORT) |
| May 28, 2026 11:02 am | — | UBS | $135.00 | $66.65 | TheFly | Corcept Therapeutics price target raised to $135 from $110 at Canaccord |
| May 13, 2026 9:34 am | — | UBS | $72.00 | $51.16 | TheFly | Corcept Therapeutics upgraded to Buy from Neutral at UBS |
| May 4, 2026 10:10 am | — | H.C. Wainwright | $75.00 | $51.42 | TheFly | Corcept Therapeutics price target raised to $75 from $60 at H.C. Wainwright |
| May 1, 2026 11:02 am | — | Piper Sandler | $88.00 | $46.52 | TheFly | Corcept Therapeutics price target raised to $88 from $73 at Piper Sandler |
| February 20, 2026 11:05 am | — | H.C. Wainwright | $67.00 | $34.24 | TheFly | Corcept Therapeutics price target lowered to $67 from $105 at H.C. Wainwright |
| January 23, 2026 11:49 am | — | Canaccord Genuity | $100.00 | $41.30 | TheFly | Corcept Therapeutics price target raised to $100 from $99 at Canaccord |
| January 22, 2026 5:41 pm | Swayampakula Ramakanth | H.C. Wainwright | $105.00 | $41.47 | TheFly | Corcept Therapeutics price target raised to $105 from $90 at H.C. Wainwright |
| January 2, 2026 11:34 am | Swayampakula Ramakanth | H.C. Wainwright | $90.00 | $36.35 | StreetInsider | Corcept Therapeutics (CORT) PT Lowered to $90 at H.C. Wainwright |
| January 2, 2026 11:22 am | Edward Nash | Canaccord Genuity | $99.00 | $36.90 | StreetInsider | Corcept Therapeutics (CORT) PT Lowered to $99 at Canaccord Genuity |
Latest News for CORT
The transaction realized $1.9 million in gross proceeds on July 7, 2026, at a weighted average price of $93.13 per share. The disposition was a cashless exercise of 20,000 options at a strike price of $21.65, followed by an immediate open-market sale.
Corcept Therapeutics maintains a Buy rating, supported by robust revenue growth, pipeline progress, and strong management execution. Relacorilant's FDA approval in ovarian cancer and likely approval in Cushing's syndrome could drive CORT revenues above $3 billion annually by decade's end. 2026 revenue guidance of $950M–$1.05B reflects >30% YoY growth, with minimal impact expected from generic competition due to…
Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.
NEW YORK, June 25, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Corcept Therapeutics Incorporated failed to disclose adverse facts concerning potential FDA approval of one of the Company's…
CORT resubmits relacorilant NDA for Cushing's syndrome, with updated analyses and data from multiple clinical studies supporting the filing.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CORT.
U.S. House Trading
No House trades found for CORT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.